Insilico Medicine

Insilico Medicine: End-to-End AI Drug Discovery Platform

Insilico Medicine is AI drug discovery company with end-to-end generative chemistry, target identification, and clinical trial design tools. Insilico has been one of the longest-running and most-published AI drug-discovery companies. Unlike newer entrants that focus on a single step in the pipeline, Insilico spans the entire R&D workflow with its Pharma.AI platform. INS018_055 (idiopathic pulmonary fibrosis) reaching Phase II clinical trials in 2024 was a significant validation moment — one of the first AI-generated molecules to demonstrate clinical efficacy signal in humans.

Key Features

• AI drug discovery company with end-to-end generative chemistry, target identification, and clinical trial design tools
• Founded in 2014 by Alex Zhavoronkov, PhD
• Headquartered in Hong Kong with operations in the United States, China, and Canada
• Approximately $1.5 billion valuation; over $400M raised across rounds
• Backed by Warburg Pincus, Sanofi, B Capital, and other strategic investors
• Multiple INDs filed with the FDA including INS018_055 for idiopathic pulmonary fibrosis
• Pharma.AI platform spans target discovery, generative chemistry, and clinical trial design

Ideal Use Case

Pharmaceutical R&D teams, biotech investors, and academic researchers leveraging AI to accelerate the drug-discovery pipeline from target identification through clinical trial design. Insilico operates both as a software platform vendor and as an in-house drug developer.

Why Use Insilico Medicine

Insilico has been one of the longest-running and most-published AI drug-discovery companies. Unlike newer entrants that focus on a single step in the pipeline, Insilico spans the entire R&D workflow with its Pharma.AI platform. INS018_055 (idiopathic pulmonary fibrosis) reaching Phase II clinical trials in 2024 was a significant validation moment — one of the first AI-generated molecules to demonstrate clinical efficacy signal in humans.

FAQ

Q: Who founded Insilico Medicine? A: Alex Zhavoronkov, PhD founded Insilico Medicine in 2014.

Q: How much has Insilico Medicine raised? A: Over $400M across multiple funding rounds, reaching an approximate $1.5 billion valuation.

Q: Who has invested in Insilico Medicine? A: Warburg Pincus, Sanofi, B Capital Group, and other pharma-aligned strategic investors.

Q: What is INS018_055? A: INS018_055 is Insilico's flagship internally developed drug candidate for idiopathic pulmonary fibrosis. It is one of the first fully AI-generated molecules to reach Phase II human clinical trials.

Q: Insilico vs Recursion vs Xaira? A: Each focuses on a different angle. Recursion emphasizes phenotypic screening with wet-lab automation. Xaira is foundation-scale generative protein design. Insilico spans the full pipeline from target discovery to clinical trial design.

tl;dr

Insilico Medicine is the AI drug discovery company with end-to-end Pharma.AI platform spanning target ID, generative chemistry, and clinical trial design. $1.5B valuation; $400M+ raised; backed by Warburg Pincus, Sanofi, B Capital. INS018_055 in Phase II for idiopathic pulmonary fibrosis.

Related

Looking for more options? Browse the Healthcare directory or read our best AI healthcare tools listicle. Insilico Medicine is also tracked on Crunchbase.